At the beginning of PD-1 treatment, 42 ICC patients used different PD-1 antibodies as follows: nivolumab (n = 3), pembrolizumab (n = 11), sintilimab (n = 14), toripalimab (n = 9), camrelizumab (n = 4), and tislelizumab (n = 1). Here, PDCD1 is linked to intrahepatic cholangiocarcinoma.